Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical KB105 for TGM1-deficient ARCI
NCT04047732Phase 2Unknown
- Sponsor
- Krystal Biotech, Inc.
- Start
- Aug 2019
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of KB105 in autosomal recessive congenital ichthyosis (ARCI), sponsored by Krystal Biotech, Inc.. Status: unknown.
02
Drugs
KB105
03
Conditions
autosomal recessive congenital ichthyosis (ARCI)
Beyond the preview
Go deeper on NCT04047732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047732.